- Home
- GOSS
GOSS
Gossamer Bio Inc.
as 09-18-2025 4:00pm EST
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 586.6M | IPO Year: | 2019 |
| Target Price: | $8.60 | AVG Volume (30 days): | 4.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.66 - $3.60 | Next Earning Date: | 11-06-2025 |
| Revenue: | $40,237,000 | Revenue Growth: | -58.02% |
| Revenue Growth (this year): | -67.34% | Revenue Growth (next year): | 34.10% |
Stock Insider Trading Activity of Gossamer Bio Inc. (GOSS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Milligan Sandra | GOSS | N/A | Aug 19 '25 | Buy | $1.92 | 26,050 | $50,016.00 | 58,050 |
Latest Gossamer Bio Inc. News
GOSS Breaking Stock News: Dive into GOSS Ticker-Specific Updates for Smart Investing
Insider Monkey
a month ago
H.C. Wainwright and Leerink Partners Reiterate ‘Buy’ Ratings on Gossamer Bio, Inc. (GOSS)
Insider Monkey
3 months ago
Gossamer Bio Completes Enrollment for Phase 3 PROSERA Study of PAH Drug Seralutinib
Business Wire
3 months ago
Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH
Business Wire
3 months ago
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
4 months ago
Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream
Thomson Reuters StreetEvents
4 months ago
Q1 2025 Gossamer Bio Inc Earnings Call
GuruFocus.com
4 months ago
Gossamer Bio Inc (GOSS) Q1 2025 Earnings Call Highlights: Strategic Progress Amid Financial ...
Zacks
4 months ago
Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates
Compare GOSS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GOSS Gossamer Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.